Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 801 to 810 of 1090 total matches.
Remimazolam (Byfavo) for Short-Term Procedural Sedation
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022 (Issue 1644)
and the sedative-hypnotic drug propofol
are commonly used for short-term procedural
sedation. Depending ...
The FDA has approved remimazolam (Byfavo – Acacia
Pharma), an ultra-short-acting IV benzodiazepine,
for induction and maintenance of sedation in adults
undergoing procedures of up to 30 minutes' duration.
Relyvrio for ALS
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
studies, the combination was
associated with stillbirth.
DRUG INTERACTIONS ― Bile acid sequestrants (e.g ...
The FDA has approved Relyvrio (Amylyx), a fixed-dose
combination of sodium phenylbutyrate and
taurursodiol, for treatment of amyotrophic lateral
sclerosis (ALS). Sodium phenylbutyrate (Buphenyl,
and others) has been available by prescription
for years for treatment of urea cycle disorders.
Taurursodiol (tauroursodeoxycholic acid), a derivative
of ursodiol, is an over-the-counter bile acid
supplement claimed to have neuroprotective
benefits. Relyvrio is the third drug to be approved
in the US for treatment of ALS; riluzole (Rilutek, and
others) and edaravone (Radicava, Radicava...
Transdermal Dextroamphetamine (Xelstrym) for ADHD
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
II controlled
substances.
DRUG INTERACTIONS — Concurrent use of
dextroamphetamine and a monoamine ...
The FDA has approved a dextroamphetamine
transdermal patch (Xelstrym – Noven) for once-daily
treatment of attention-deficit/hyperactivity disorder
(ADHD) in patients ≥6 years old. Xelstrym is the first
transdermal amphetamine product to be approved
in the US. A methylphenidate transdermal patch
(Daytrana, and generics) has been available for years
for treatment of ADHD.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):22-4 doi:10.58347/tml.2023.1669d | Show Introduction Hide Introduction
Alvimopan (Entereg) for Postoperative Ileus
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008 (Issue 1300)
EDITORIAL FELLOW: Lauren K. Schwartz, M.D., Mount Sinai School of Medicine
DRUG INTERACTIONS FELLOW ...
The FDA has approved the marketing of alvimopan (Entereg - Adolor/GlaxoSmithKline), a selective muopioid receptor antagonist, for oral treatment of postoperative ileus after bowel resection. The only other drug in this class available in the US is subcutaneously injected methylnaltrexone (Relistor), which is approved for treatment of opioid-induced constipation in patients with advanced illness receiving palliative care.
Tolvaptan (Samsca) for Hyponatremia
The Medical Letter on Drugs and Therapeutics • Nov 30, 2009 (Issue 1326)
during pregnancy.
DRUG INTERACTIONS — Tolvaptan is metabolized
hepatically by CYP3A and should ...
The FDA has approved the marketing of tolvaptan (Samsca - Otsuka), an oral vasopressin receptor antagonist, for treatment of hypervolemic or euvolemic hyponatremia due to congestive heart failure (CHF), cirrhosis or the syndrome of inappropriate antidiuretic hormone secretion (SIADH). A similar drug, conivaptan (Vaprisol) is already available for intravenous (IV) treatment of euvolemic hyponatremia in hospitalized patients. Tolvaptan was approved by the FDA for both inpatient and outpatient use, but it should be started in a hospital.
Sarecycline (Seysara) - Another Oral Tetracycline for Acne
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019 (Issue 1568)
in ...
Sarecycline (Seysara — Allergan), a new oral
tetracycline antibiotic, has been approved by the FDA
for once-daily treatment of inflammatory lesions of
non-nodular moderate to severe acne in patients ≥9
years old.
A Progestin Implant (Implanon) for Long-Term Contraception
The Medical Letter on Drugs and Therapeutics • Oct 09, 2006 (Issue 1245)
.
DRUG INTERACTIONS — Inhibition of CYP3A may
increase serum etonogestrel concentrations and the
risk ...
Implanon (Organon), an implantable contraceptive containing the progestin etonogestrel, has been approved by the FDA. Two other implantable contraceptives, Norplant and Jadelle, which both contain levonorgestrel, are FDA-approved but not marketed in the US.
Valproic Acid Delayed Release (Stavzor)
The Medical Letter on Drugs and Therapeutics • Apr 06, 2009 (Issue 1309)
DeVane. Pharmacokinetics, drug interactions and tolerability of valproate. Psychopharmacol Bull 2003; 37 ...
The FDA has approved a delayed-release capsule formulation of valproic acid (VPA; Stavzor - Noven Therapeutics) for all of the indications for which divalproex sodium (Depakote, and others; Depakote ER) is approved: monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures, and adjunctive therapy in patients with multiple seizure types that include absence seizures; acute treatment of manic episodes associated with bipolar disorder; and prophylaxis of migraine headaches. In addition, valproate (valproic acid or divalproex sodium) is considered a...
Romidepsin (Istodax) for Cutaneous T-Cell Lymphoma
The Medical Letter on Drugs and Therapeutics • May 31, 2010 (Issue 1339)
. It is classified as category D for use in
pregnancy (positive evidence of risk).
DRUG INTERACTIONS — Romidepsin ...
The FDA has approved romidepsin (Istodax – Celgene), an IV histone deacetylase (HDAC) inhibitor,
for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic
therapy. The most common types of CTCL are mycosis fungoides, a low-grade lymphoma usually confined to
the skin, and Sézary syndrome, a more aggressive disease with malignant lymphocytes in the blood. Both
can progress to fatal systemic involvement. Romidepsin is the second HDAC inhibitor approved for
this indication; vorinostat (Zolinza), an oral HDAC inhibitor, was approved...
Tranexamic Acid (Lysteda) for Treatment of Menorrhagia
The Medical Letter on Drugs and Therapeutics • Jul 12, 2010 (Issue 1342)
.
DRUG INTERACTIONS — Tranexamic acid should
not be used concurrently with estrogen-containing hormonal ...
The FDA has approved the use of tranexamic acid (Lysteda – Ferring), an oral antifibrinolytic, for treatment of menorrhagia. Tranexamic acid has been used for this purpose in Europe for decades, and is available without a prescription in some countries. It has been available in the US since 1987 for use with coagulation factors in patients with hemophilia undergoing dental extractions.